{"id":"W4283797772","doi":"10.1016/j.msard.2022.104031","title":"Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis","year":2022,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"EVERSANA (Canada)","funders":"University of Bristol; Novartis Animal Health; Novartis","keywords":"Ocrelizumab; Medicine; Relapsing remitting; Ofatumumab; Multiple sclerosis; Internal medicine; Filgrastim; Oncology; Physical therapy; Dermatology; Rituximab; Immunology; Granulocyte colony-stimulating factor; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003197105,0.000545827,0.001462345,0.0004869128,0.001044233,0.00001866057,0.0002172073,0.0001705675,0.00004368367],"category_scores_gemma":[0.0006372107,0.0003525729,0.0004420187,0.0008063469,0.0003752633,0.0001074001,0.0001931608,0.0002708893,4.155267e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007444164,"about_ca_system_score_gemma":0.0001189726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002181246,"about_ca_topic_score_gemma":0.001930228,"domain_scores_codex":[0.9964815,0.0001772329,0.001225381,0.000754551,0.0006227736,0.0007386032],"domain_scores_gemma":[0.9955696,0.003069583,0.0004327973,0.0005739706,0.0002124417,0.0001415538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02623581,0.01684649,0.7904703,0.0001225304,0.001598441,6.455434e-7,0.01697849,0.06060003,0.001511766,0.000008955853,0.00006144982,0.08556505],"study_design_scores_gemma":[0.1435101,0.01614638,0.7559604,0.0002940295,0.000351861,1.382773e-7,0.004184636,0.07748957,0.0006222769,0.000003799476,0.001115163,0.0003216917],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877119,0.002735166,0.00002649602,0.0007958834,0.0002495846,0.007927489,0.0004815687,0.00004408429,0.00002784053],"genre_scores_gemma":[0.9942235,0.003406313,0.0005576387,0.00001442429,0.00001005792,0.00128749,0.0003295791,0.00008873294,0.00008231406],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1172743,"threshold_uncertainty_score":0.9998927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07481059588906752,"score_gpt":0.3151139462203904,"score_spread":0.2403033503313229,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}